Evidence map›Paper›PMID 32246253›Full record

SynthesisJournal of neurology2020

GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis.

Konark Malhotra, Aristeidis H Katsanos, Vaia Lambadiari, Nitin Goyal, Lina Palaiodimou, Maria Kosmidou, Christos Krogias, Andrei V Alexandrov, Georgios Tsivgoulis

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 4 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022
    Guideline
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Konark MalhotraDepartment of Neurology, Allegheny Health Network, Pittsburgh, PA, USA. konark.malhotra@yahoo.com.
Aristeidis H KatsanosDivision of Neurology, McMaster University/Population Health Research Institute, Hamilton, Canada.
Vaia LambadiariSecond Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, "Attikon" University Hospital, Athens, Greece.
Nitin GoyalDepartment of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
Lina PalaiodimouSecond Department of Neurology, "Attikon" University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Maria KosmidouFirst Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Christos KrogiasDepartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Andrei V AlexandrovDepartment of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
Georgios TsivgoulisDepartment of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA.
National and Kapodistrian University of Athens · GRUniversity of Tennessee Health Science Center · USAllegheny Health Network · USPopulation Health Research Institute · CARuhr University Bochum · DEUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomized controlled clinical trials (RCT) have demonstrated varied efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists for cardiovascular outcomes. We sought to evaluate the efficacy and safety of GLP-1R agonists among patients with Type 2 diabetes mellitus (DM) for stroke prevention.

methodsWe conducted a systematic review and meta-analysis of RCTs reporting the following outcomes among patients with Type 2 DM treated with GLP-1R agonists (vs. placebo): nonfatal or fatal strokes, all-cause or cardiovascular mortality, myocardial infarction (MI) and major adverse cardiovascular events (MACE). The protocol of our systematic review and meta-analysis was registered to the PROSPERO database. We pooled odds ratios (OR) using random-effect models, and assessed the heterogeneity using Cochran Q and I

resultsWe identified 8 RCTs, comprising 56,251 patients. In comparison to placebo, GLP-1R agonists reduced nonfatal strokes (OR 0.84; 95% CI 0.76-0.94, p = 0.002; I

conclusionsAmong patients with type 2 DM, GLP-1R agonists are beneficial for primary stroke, MACE, and cardiovascular mortality prevention. Further RCTs are needed to evaluate their role for secondary stroke prevention.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2HumansHypoglycemic AgentsStrokeGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDiabetes mellitusGLP-1 analogsPreventionStroke

Identifiers

PMID32246253
OpenAlexW3014553064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.